Stephen Toovey
Direktor/Vorstandsmitglied bei 60 DEGREES PHARMACEUTICALS, INC.
Vermögen: 3 542 $ am 30.06.2024
Aktive Positionen von Stephen Toovey
| Unternehmen | Position | Beginn | Ende |
|---|---|---|---|
| 60 DEGREES PHARMACEUTICALS, INC. | Direktor/Vorstandsmitglied | 12.07.2023 | - |
| Independent Dir/Board Member | 12.07.2023 | - |
Karriereverlauf von Stephen Toovey
Ehemalige bekannte Positionen von Stephen Toovey
| Unternehmen | Position | Beginn | Ende |
|---|---|---|---|
Shanghai Ark Biopharmaceutical Co., Ltd.
 Shanghai Ark Biopharmaceutical Co., Ltd. Pharmaceuticals: MajorHealth Technology Shanghai Ark Biopharmaceutical Co., Ltd. engages in biopharmaceutical services. It is a biopharmaceutical company which focuses on the discovery and development of novel therapeutics addressing unmet medical needs in respiratory and lung diseases. The firm’s product portfolio covering full disease cycle and patient segmentations, its drug candidates addresses a spectrum of acute and chronic respiratory and lung diseases. The company was founded by Jim Zhen WU and Wu Zheng Bo in April 2014 and is headquartered in Shanghai, China. | Gründer | 01.01.2014 | 01.01.2020 |
Ausbildung von Stephen Toovey
| Ghent University | Doctorate Degree |
Statistik
International
| 2 | |
| Belgien | 2 |
| China | 2 |
Operativ
| Director/Board Member | 1 |
| Independent Dir/Board Member | 1 |
| Doctorate Degree | 1 |
Sektoral
| Consumer Services | 2 |
| Health Technology | 2 |
Besetzte Positionen
Aktive
Inaktive
Börsennotierte Unternehmen
Private Unternehmen
Unternehmensverbindungen
| Private Unternehmen | 2 |
|---|---|
| 60 Degrees Pharmaceuticals, Inc. | |
Shanghai Ark Biopharmaceutical Co., Ltd.
Shanghai Ark Biopharmaceutical Co., Ltd. Pharmaceuticals: MajorHealth Technology Shanghai Ark Biopharmaceutical Co., Ltd. engages in biopharmaceutical services. It is a biopharmaceutical company which focuses on the discovery and development of novel therapeutics addressing unmet medical needs in respiratory and lung diseases. The firm’s product portfolio covering full disease cycle and patient segmentations, its drug candidates addresses a spectrum of acute and chronic respiratory and lung diseases. The company was founded by Jim Zhen WU and Wu Zheng Bo in April 2014 and is headquartered in Shanghai, China. | Health Technology |
- Börse
- Insiders
- Stephen Toovey
- Erfahrung
